Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis:
There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis ease. Mechanisms ofirreversible axonal damage and the role pla...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Milano
Springer Milan
2004
|
| Schriftenreihe: | Topics in Neuroscience
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis ease. Mechanisms ofirreversible axonal damage and the role played by the inter action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today |
| Beschreibung: | 1 Online-Ressource (XV, 199 p) |
| ISBN: | 9788847021174 |
| DOI: | 10.1007/978-88-470-2117-4 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145361 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9788847021174 |9 978-88-470-2117-4 | ||
| 024 | 7 | |a 10.1007/978-88-470-2117-4 |2 doi | |
| 035 | |a (ZDB-2-SME)978-88-470-2117-4 | ||
| 035 | |a (OCoLC)1118992185 | ||
| 035 | |a (DE-599)BVBBV046145361 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.8 |2 23 | |
| 084 | |a YG 6003 |0 (DE-625)153507:12909 |2 rvk | ||
| 245 | 1 | 0 | |a Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis |c edited by Otto R. Hommes, Giancarlo Comi |
| 264 | 1 | |a Milano |b Springer Milan |c 2004 | |
| 300 | |a 1 Online-Ressource (XV, 199 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Topics in Neuroscience | |
| 520 | |a There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis ease. Mechanisms ofirreversible axonal damage and the role played by the inter action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today | ||
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Neuroradiology | |
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Radiology, Medical | |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Frühdiagnostik |0 (DE-588)4113642-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Multiple Sklerose |0 (DE-588)4040693-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Multiple Sklerose |0 (DE-588)4040693-3 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Multiple Sklerose |0 (DE-588)4040693-3 |D s |
| 689 | 1 | 1 | |a Frühdiagnostik |0 (DE-588)4113642-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Hommes, Otto R. |4 edt | |
| 700 | 1 | |a Comi, Giancarlo |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847021716 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847001954 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847021181 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-88-470-2117-4 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525546 | ||
| 966 | e | |u https://doi.org/10.1007/978-88-470-2117-4 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180481909981184 |
|---|---|
| any_adam_object | |
| author2 | Hommes, Otto R. Comi, Giancarlo |
| author2_role | edt edt |
| author2_variant | o r h or orh g c gc |
| author_facet | Hommes, Otto R. Comi, Giancarlo |
| building | Verbundindex |
| bvnumber | BV046145361 |
| classification_rvk | YG 6003 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-88-470-2117-4 (OCoLC)1118992185 (DE-599)BVBBV046145361 |
| dewey-full | 616.8 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8 |
| dewey-search | 616.8 |
| dewey-sort | 3616.8 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-88-470-2117-4 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03493nmm a2200589zc 4500</leader><controlfield tag="001">BV046145361</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9788847021174</subfield><subfield code="9">978-88-470-2117-4</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-88-470-2117-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-88-470-2117-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118992185</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145361</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 6003</subfield><subfield code="0">(DE-625)153507:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis</subfield><subfield code="c">edited by Otto R. Hommes, Giancarlo Comi</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Milano</subfield><subfield code="b">Springer Milan</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XV, 199 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Topics in Neuroscience</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis ease. Mechanisms ofirreversible axonal damage and the role played by the inter action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroradiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology, Medical</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Frühdiagnostik</subfield><subfield code="0">(DE-588)4113642-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Frühdiagnostik</subfield><subfield code="0">(DE-588)4113642-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hommes, Otto R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Comi, Giancarlo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847021716</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847001954</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847021181</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-88-470-2117-4</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525546</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-88-470-2117-4</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046145361 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:27Z |
| institution | BVB |
| isbn | 9788847021174 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525546 |
| oclc_num | 1118992185 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XV, 199 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Springer Milan |
| record_format | marc |
| series2 | Topics in Neuroscience |
| spelling | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis edited by Otto R. Hommes, Giancarlo Comi Milano Springer Milan 2004 1 Online-Ressource (XV, 199 p) txt rdacontent c rdamedia cr rdacarrier Topics in Neuroscience There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis ease. Mechanisms ofirreversible axonal damage and the role played by the inter action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today Neurology Neuroradiology Radiology, Medical Therapie (DE-588)4059798-2 gnd rswk-swf Frühdiagnostik (DE-588)4113642-1 gnd rswk-swf Multiple Sklerose (DE-588)4040693-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Multiple Sklerose (DE-588)4040693-3 s Therapie (DE-588)4059798-2 s DE-604 Frühdiagnostik (DE-588)4113642-1 s Hommes, Otto R. edt Comi, Giancarlo edt Erscheint auch als Druck-Ausgabe 9788847021716 Erscheint auch als Druck-Ausgabe 9788847001954 Erscheint auch als Druck-Ausgabe 9788847021181 https://doi.org/10.1007/978-88-470-2117-4 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis Neurology Neuroradiology Radiology, Medical Therapie (DE-588)4059798-2 gnd Frühdiagnostik (DE-588)4113642-1 gnd Multiple Sklerose (DE-588)4040693-3 gnd |
| subject_GND | (DE-588)4059798-2 (DE-588)4113642-1 (DE-588)4040693-3 (DE-588)4143413-4 |
| title | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis |
| title_auth | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis |
| title_exact_search | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis |
| title_full | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis edited by Otto R. Hommes, Giancarlo Comi |
| title_fullStr | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis edited by Otto R. Hommes, Giancarlo Comi |
| title_full_unstemmed | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis edited by Otto R. Hommes, Giancarlo Comi |
| title_short | Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis |
| title_sort | early indicators early treatments neuroprotection in multiple sclerosis |
| topic | Neurology Neuroradiology Radiology, Medical Therapie (DE-588)4059798-2 gnd Frühdiagnostik (DE-588)4113642-1 gnd Multiple Sklerose (DE-588)4040693-3 gnd |
| topic_facet | Neurology Neuroradiology Radiology, Medical Therapie Frühdiagnostik Multiple Sklerose Aufsatzsammlung |
| url | https://doi.org/10.1007/978-88-470-2117-4 |
| work_keys_str_mv | AT hommesottor earlyindicatorsearlytreatmentsneuroprotectioninmultiplesclerosis AT comigiancarlo earlyindicatorsearlytreatmentsneuroprotectioninmultiplesclerosis |